Ano‐genital granulomatosis treated with ciprofloxacin

Roé, Esther; Barnadas, M.A.; Bergua, Paula; Sancho, Félix Valcárcel; Matas, Laia; Paredes, R; Pujol, Jordi; Alomar, A.

doi:10.1111/j.1468-3083.2008.02710.x

Cited by 8 publications

(3 citation statements)

References 6 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, longterm metronidazole is associated with peripheral neuropathy, which can limit its continued use [13]. With the advent of biological agents, several studies have reported excellent outcomes with infliximab and azathioprine [3,4,[6][7][8][9][10][11][12][13][14][15] among others like ustekinumab, which have shown rapid resolution of symptoms similar to the outcome in our patient [15].…”

Section: Discussionmentioning

confidence: 68%

“…Most studies suggest that a definitive diagnosis of Crohn’s disease is best made with a biopsy of the lesion, which shows non-caseating granulomas and chronic inflammatory change in the background [ 8 ]. Some studies have classified lesions with granulomas as vulval granulomatosis in the absence of Crohn’s disease [ 9 ]. However, having biopsy-confirmed diagnoses is not agreed upon.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab

Lim¹,

Singh²

2021

Cureus

View full text Add to dashboard Cite

Vulval Crohn's disease is a rare manifestation of Crohn's disease. Although it is usually caused by a fistulating process, it may be a result of a metastatic disease process as well, the exact mechanisms of which are not well understood yet. Vulval Crohn's disease may occur before the onset of bowel symptoms and may continue to be active while bowel symptoms are quiescent. Coupled with the fact that most vulval Crohn's lesions are similar to other disease processes, it can prove to be a diagnostic challenge. Due to its rarity, no guidelines for treatment exist; however, most reports agree that when symptoms are not controlled with antibiotics and topical steroids, immunosuppressive medications such as oral steroids and biological agents are the way forward. Although surgery may be an option, data suggest that its use is scarce. We report the case of a 47-year-old Caucasian woman with bilateral metastatic vulval Crohn's disease from a district hospital in the United Kingdom who responded well to ustekinumab. This is one of the first few cases reporting good clinical outcomes with the agent.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab

Lim¹,

Singh²

2021

Cureus

View full text Add to dashboard Cite

show abstract

“…If no evidence of Crohn's disease is found at that time, the disease can simply be labeled as anogenital granulomatosis. Treatment is similar regardless of the diagnosis as cutaneous Crohn's disease or anogenital granulomatosis of unknown origin [10].…”

Section: Discussionmentioning

confidence: 99%

Delayed Diagnosis of Vulvar Crohn’s Disease in a Patient with No Gastrointestinal Symptoms

Wells

Cohen²

2018

Case Rep Dermatol

View full text Add to dashboard Cite

Though Crohn’s disease primarily affects the gastrointestinal tract, cutaneous Crohn’s disease of the vulva can occur in the absence of gastrointestinal symptoms, complicating the diagnosis. Once clinicians suspect cutaneous Crohn’s disease, antibiotics and traditional immunosuppressants comprise initial treatment. Unfortunately, sometimes these therapies are not effective, or they provide only short-lived symptomatic improvement. A few case reports have found tumor necrosis factor-α inhibitors to be helpful in such refractory cases. We describe a patient with long-standing, painful vulvar Crohn’s lesions with no gastrointestinal manifestations of the disease. Her diagnosis was delayed for years, and initial therapy with antibiotics and steroids was unsuccessful. Finally, the patient experienced effective and long-lasting symptom improvement with infliximab (Remicade^TM).

show abstract